{"name":"Bellus Health Inc. - a GSK company","slug":"bellus-health-inc-a-gsk-company","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BLU-5937","genericName":"BLU-5937","slug":"blu-5937","indication":"Chronic cough","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"3APS","genericName":"3APS","slug":"3aps","indication":"Chronic cough (idiopathic pulmonary fibrosis-associated cough)","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Tramiprosate (3APS)","genericName":"Tramiprosate (3APS)","slug":"tramiprosate-3aps","indication":"Mild cognitive impairment due to Alzheimer's disease","status":"phase_3"}]}],"pipeline":[{"name":"BLU-5937","genericName":"BLU-5937","slug":"blu-5937","phase":"phase_3","mechanism":"BLU-5937 is a selective P2X3 receptor antagonist that blocks pain signaling in sensory neurons.","indications":["Chronic cough","Refractory chronic cough"],"catalyst":""},{"name":"3APS","genericName":"3APS","slug":"3aps","phase":"phase_3","mechanism":"3APS is a selective P2X3 receptor antagonist that blocks pain signaling in sensory neurons to reduce chronic cough.","indications":["Chronic cough (idiopathic pulmonary fibrosis-associated cough)","Refractory chronic cough"],"catalyst":""},{"name":"Tramiprosate (3APS)","genericName":"Tramiprosate (3APS)","slug":"tramiprosate-3aps","phase":"phase_3","mechanism":"Tramiprosate inhibits amyloid-beta aggregation and promotes its clearance, reducing amyloid plaque formation in the brain.","indications":["Mild cognitive impairment due to Alzheimer's disease","Mild dementia due to Alzheimer's disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOUVFZblNLa1VORlBwc3dEZk1JbU9ySVJDdEdIZEdOXzVoN1hsU0cwRFltbVQ2TGczdjJUZ210dFNzTVJnTGxtSWxRcTNwbUZQOHNXZVYySTNTc3lzM0NnYmYzREhuQXdvQTI2ZjFEYmNrS1NPXzdNRzc3ajNUWWhvZ1kxVEZrazZJQTkwdS1B?oc=5","date":"2023-09-06","type":"pipeline","source":"Yahoo Finance","summary":"Chronic Refractory Cough Market to Observe Stupendous Growth by 2032, Assesses DelveInsight | Key Players to Watch Out - Merck, Kyorin, NeRRe, Bellus Health, GSK, Axalbion, Aldeyra, Genentech - Yahoo ","headline":"Chronic Refractory Cough Market to Observe Stupendous Growth by 2032, Assesses DelveInsight | Key Players to Watch Out -","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQMXI5YXNzemJuVXdEY0VGaHNiajNabG5EQ3dUSGhLU1drYlZSLS05aFJRc0NNY0lBTEFVR1Z0dkFtSWxqWC10cjc2SzViYlEwZkx2VDh3bWpjaU5SZHFjak8xbEg3eVNiUFN3T216NUItdzU1T04zR2FNbEpUVkhCMllUc2NzeVU2T2hqY0syVzdTcVk?oc=5","date":"2023-06-16","type":"regulatory","source":"The Globe and Mail","summary":"Bellus shareholders approve US$2-billion takeover by GSK; deal set to close this month - The Globe and Mail","headline":"Bellus shareholders approve US$2-billion takeover by GSK; deal set to close this month","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQT3pIVU84TERpUEFXX0ZMN1VSRUYwZGdRc2lJMUdpMHYtTDhFNnFiRGRTdHRfZUpfa191eXhBUlA2M20xM09YdHhqelNEUnFFaGdZTTJBZ1ZSc3BIMDJlZnVJbkQ5ZlZPNHV3akRMWXN6a1dnQXA4aTI0NW5oU1oxNGcwMWphZFR6bHl0SzdqVWlFQQ?oc=5","date":"2023-06-12","type":"deal","source":"The Globe and Mail","summary":"Novartis buys Chinook for US$3.2-billion, latest in string of big exits for Canadian biotechs - The Globe and Mail","headline":"Novartis buys Chinook for US$3.2-billion, latest in string of big exits for Canadian biotechs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQb25VSXc5VC0wbVN6UDJodEQ3bHlZNGZZZFlubGNqVmd4bjlwRHlRWE42dmJkcDE5Rkd4SHBvYW40ZUtUYXlHXzFhbmVYcjVhS0x3ZjNuSjNBMDlpY1hrUVUySkpUQWd3OEFMZGZxRUhuVzd1UWpfM2ZTdHI1LXhWRy1LbDlRUEt4QUZNdFpleVF6RFhwdmE3TnZQTy1uSktVQUtPbDZVNTNtTmtsdnN6aGRzU0wtVlgwakQzUVpEOTdtWFp6LVlYdGYweGhIV1djcERoakhrYVRyTjZzMVE?oc=5","date":"2023-05-16","type":"pipeline","source":"Business Wire","summary":"BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition - Business Wire","headline":"BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxNdklyVldxTWdsbkRRWmp2VkgwdXJTU1NURHZnSEs2V1JPQ1dYU1pjZGY4RG5zNW5sRWNoSm5feE5peGV5YUlQYnp3XzVIak1INlVYWDA5MnAwczBkeGM1eHo3WlZQblRLSjJkdFFnSURyX25fODhmQS1BZnVkejhSYmNncERHUkp5WTFZdWVKaWhEcWpaOGZiMTROb3NEbUZLNmlIeVFWNkxrWkM0UE44cFVnWDV5X1ZvamZqcGlETHNFdWVtNDcxRDR4b3VSbFpXcmNZWjJR?oc=5","date":"2023-05-12","type":"earnings","source":"Business Wire","summary":"BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights - Business Wire","headline":"BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPWk9GY3RMTFpmQVZIU21qX1p6YXQyYkhrck1qYWtoNHNPWDRXbXQ1ZjZYUUYwR1pfU3dqOUp5U2c1ckczaEhvOGRiWW5ta1ZFUkQ5VmdQQ1Utdjl4dUx6bGR2WTRXMmhVSkRPTGRSR2pfVFdfNUZLNFNwVHYyMkE5ak1pdnluak83VTBlTHBsdGdmZVRNM1dTYVR0MXRlMThNM2xueFZaQXpGSllDUTlDVWVmNVjSAXJBVV95cUxOTVBvWVFLZVlISm5DdjBJTkFuSzhYclBNNzFncWZnd2daTlpCT0VwRGRway1IZzFMamR6RDNWSV9aWXA3YjdYT1E2SC1ZY3JxM01FQ1pBN0pGVGNFbTlPcUdQejh1QXBtaUZrZkVUWXN0emc?oc=5","date":"2023-05-08","type":"deal","source":"Law360","summary":"Paul Weiss' Veeraraghavan On Slew Of Health Care Deals - Law360","headline":"Paul Weiss' Veeraraghavan On Slew Of Health Care Deals - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxPN3BERU01VC1LczUyWXBUTUd3bDZ5eUNfWHd3cFB1OWk4eTBNbFhkSU9zZF8zTU5OcEhHQlZEVjJUVFRqVjlPT3NQd25RMVo1NlAwbkh2SDBUSV9ySWltZ3RfZlB6dmp3MDRROHpSbkd5X2FPV1VpQWgyUUlxbFZrNXJYOUtCeU83SjM4Y1UtMHRZclVPSWVNMS1CWFBTQl9BZTlId1BOX0x3bWk1NWRPVEpsRjE1aEwxVzlxdEV6NFFQQkwyTU1SM0VR?oc=5","date":"2023-04-18","type":"deal","source":"GSK US","summary":"GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health - GSK US","headline":"GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPSGxTSjRsS1BiZk1hbWJoUndIaFQ3VXI2LV8td2hJcnNUUFlNdGRtNEtUUEtXVlZuaGNPQnpac1E0d3o3c0VFbWY2SFRkTzNaN0Z0MDdvZmhrNzFuUklFM3F6UGxKOFZzNWVWTFVDZE5RdjZMQkZQbFg3T05TWXZHN0pWdnFQSWE1ZlMwb0RoY1M?oc=5","date":"2023-04-18","type":"deal","source":"BioPharma Dive","summary":"GSK to buy Bellus Health and its chronic cough drug for $2B - BioPharma Dive","headline":"GSK to buy Bellus Health and its chronic cough drug for $2B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPYzE3VVFZN01PTmxkc1g1ajNqYnE5LTFmcWhHcWJTNFZLZ0hPUW40Umx0dUpfUEkxOVlDZVNCazJTa0lwOUxIT3lkS21vM2FYVThOVl9SdmZNSzNJQTVVU3NCeDgxRlZQbkdLeE1GZ0VNLWlSV0NXUzJKR1RYazZFMXRaVE5wenU3d09GZjhEQXgtZzJmZ092VFFWMjJxakZNQVc4S0JvYUxLZFlpVnV2TmZ3bEdNcXRiM3lUag?oc=5","date":"2023-04-18","type":"trial","source":"Fierce Biotech","summary":"GSK coughs up $2B to buy Bellus for late-phase rival to Merck & Co.'s stuttering gefapixant - Fierce Biotech","headline":"GSK coughs up $2B to buy Bellus for late-phase rival to Merck & Co.'s stuttering gefapixant","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPOHNVdW93b0NpX1JRbXNnOFJyRUplZG50Y0liZmRvM0ZlRHN5RkZUaXNUVHFaQ29UY3ZJR0RER1pIU3BWcGpqdTh1ZWxZc3ZqeGota3N1TjlqS1hLaEV5TjA2cWtkLVRiQ0lXNE04VnRScmlkTnhBVzdXZHJYODdqbzZaaE5XUQ?oc=5","date":"2023-04-18","type":"pipeline","source":"The Globe and Mail","summary":"GSK’s $2-billion purchase of Bellus delivers second big exit for Montreal’s Bellini family - The Globe and Mail","headline":"GSK’s $2-billion purchase of Bellus delivers second big exit for Montreal’s Bellini family","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}